The appointments have been made to support the progression of Phico's lead product SASPject PT3.8 through clinical trials, and the financing of the company's planned clinical-grade manufacturing facility.
SASPject PT3.8 has been developed for the intravenous treatment of hospital infections due to the bacterium, Pseudomonas aeruginosa. using Phico's SASPject platform, which utilises unique antibacterial small acid-soluble spore proteins to target and deactivate bacterial DNA.
Andrew Armour is a Chartered Accountant with experience in the healthcare industry, particularly in financial restructuring, equity fundraising and corporate acquisitions and disposals. Andrew previously held positions at Grant Thornton and Deloitte, working on restructuring and corporate finance assignments, before becoming the FD of Colchester Hospital.
He works with the FD Centre and joins Phico as our Finance director on a part-time basis, bringing a wealth of experience in strategic financial management to support the company in its upcoming fundraising activities and partnering negotiations.
Prof Mark Wilcox has held several positions at the Leeds Teaching Hospitals and is currently a Consultant Microbiologist and Head of Research and Development in Microbiology, and Professor of Medical Microbiology at the University of Leeds.
He has a wealth of clinical experience in infectious diseases and advises Public Health England and NHS England on diagnosis, prevention and development of infection prevention and control products and new antimicrobial agents to target healthcare associated infections.
Mark has been involved with Phico for a number of years from representing the Wellcome Trust as their Expert on Phico's two WT Awards, and will now further support the company in progressing SASPject PT3.8 through clinical trials in his new role as an NED.
David Beadle has over 25 years' experience within healthcare and finance, having worked in marketing and strategic development at Schwarz Pharma and Schering AG before moving into investment banking, where he built and led highly ranked healthcare equity research teams both globally and across Europe for over 10 years.
He is specialised in consulting on scientific, corporate finance and business development strategies within the healthcare and biotechnology space. David joins Phico as an NED and will primarily advise on strategies for business development.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer